TP53 and neoplasm: In preclinical RAS pathway-activated, TP53 wild-type xenograft melanoma models (UACC62), a therapeutic benefit was observed for the SAR405838 and pimasertib combination over the activity of either single-agent; durable tumour regression was observed with the combination.13